Both MindMed and Atai Life Sciences look set to trade on the Nasdaq, presenting a trio of psychedelic companies on one of the world’s most prestigious stock exchanges. MindMed today announced their application to uplist to the Nasdaq was a success. As such, the company expects to commence trading on Tuesday April 27th, under symbol MNMD. Atai’s preliminary prospectus also published this week…
